Filing Analysis
United Health Products, Inc. has entered into an agreement with NAMSA to act as the regulatory sponsor for a new clinical study of its CelluSTAT Hemostatic Gauze. This study is a critical component of the company's FDA Premarket Approval (PMA) application process.
🚩 Red Flags
- Regulatory dependency: The company's path to commercialization for its primary product depends on successful completion of this FDA-related clinical study.
📋 Key Facts
- Agreement signed on July 7, 2026, with NAMSA, a global MedTech contract research organization.
- NAMSA will serve as the regulatory sponsor for a new clinical study of CelluSTAT Hemostatic Gauze.
- The clinical study is being conducted in connection with the company's FDA Premarket Approval (PMA) application.
United Health Products, Inc. entered into a multi-layered financing arrangement with Alumni Capital LP involving a $289,821 senior convertible promissory note and an 'Any Market Purchase Agreement' (AMPA) for up to $4,000,000 in equity. The deal includes highly dilutive terms, including a conversion price of $0.06 per share and warrants at $0.075 per share.
🚩 Red Flags
- Extreme dilution risk: The conversion price ($0.06) and warrant price ($0.075) are likely significantly below current market value in a micro-cap context.
- Death Spiral Provision: The AMPA pricing mechanism (90% of VWAP) is a classic 'death spiral' feature that causes massive dilution to existing shareholders as the stock price drops.
- High interest rate: 15% per annum on the senior note.
- Large share reservation: Company must reserve at least 20,000,000 shares for registration of conversion shares.
📋 Key Facts
- Entered into a Securities Purchase Agreement with Alumni Capital LP on December 16, 2025.
- Issued a senior convertible promissory note for $289,821 (net proceeds of $250,000) at 15% per annum interest.
- Note maturity date is December 31, 2026.
- Conversion price set at $0.06 per share.
- Entered into an AMPA allowing Alumni to purchase up to $4,000,000 of common stock in a series of purchases.
- AMPA shares are to be priced at 90% of the lowest two-day VWAP.
- Issued a 5-year warrant for 3,484,321 shares at $0.075 per share.
Kristofer Heaton has resigned from his roles as Vice President of Finance and Principal Financial Officer, effective June 12, 2025. The CEO will serve as the interim Principal Financial Officer while a replacement is sought.
🚩 Red Flags
- Sudden departure of the Principal Financial Officer (PFO) can sometimes precede financial restatements or internal control issues, though not explicitly stated here.
- Increased key-person risk as the CEO must now manage dual responsibilities (CEO and interim PFO).
📋 Key Facts
- Kristofer Heaton resigned as VP of Finance and Principal Financial Officer on June 12, 2025.
- Resignation cited 'personal and professional factors'.
- CEO Brian Thom will act as the interim Principal Financial Officer.
- The company is actively seeking a permanent replacement.
United Health Products, Inc. announced an upgrade of its common stock from the OTC Pink to the OTCQB Venture Market. The filing also provides a status update regarding the FDA Premarket Approval application for its CelluSTAT® gauze product.
🚩 Red Flags
- Regulatory risk associated with the pending FDA Premarket Approval for the primary product (CelluSTAT®).
📋 Key Facts
- Common stock upgraded from OTC Pink to OTCQB Venture Market on May 1, 2025.
- Company provided an update regarding the FDA Premarket Approval (PMA) application for CelluSTAT® gauze.
- The company refers investors to previous 10-K and 10-Q filings for specific risks related to the FDA application.
United Health Products, Inc. issued an 8-K to announce a press release regarding an update on the FDA's Premarket Approval (PMA) application for its HemoStyp® Gauze product.
🚩 Red Flags
- Regulatory dependency: The company's progress is tied to FDA approval processes which are inherently uncertain.
📋 Key Facts
- The filing relates to an update on the FDA Premarket Approval application for HemoStyp® Gauze.
- The announcement was made via a press release dated November 4, 2024.
- The company refers investors to its Form 10-Q (period ended June 30, 2024) for specific risk factors regarding this application.
United Health Products, Inc. has entered into a Second Amendment to its existing Common Stock Purchase Agreement (CSPA) with White Lion Capital, LLC. The amendment modifies the pricing mechanism for shares to be issued under the agreement.
🚩 Red Flags
- Dilutive financing structure: The amendment facilitates the issuance of common stock at significant discounts to market price (7%-10% discount).
- Potential for downward pressure on share price due to the pricing mechanism and potential volume of shares issued.
- The existence of a floor price ($0.25) suggests the company may be operating in a low-stock-price environment, typical of micro-cap distress.
📋 Key Facts
- The Second Amendment was executed on June 20, 2024.
- Pricing is set at the lower of: (i) 93% of the 5-day VWAP following exercise (or 95% if on a national exchange), or (ii) the closing price on the day of exercise.
- A floor price of $0.25 per share is established for standard transactions.
- If White Lion waives the floor price, a discounted pricing mechanism applies at 90% of the lower of the 3-day VWAP or the most recent closing price.